Valerio D. S.
- Country
- Italy
- Department
- Ematologia
Research Overview
- Pharmacokinetic Comparability Study of Pre- and Post-change Teclistamab in Relapsed/Refractory Multiple Myeloma Patients
- A Phase II Study of Teclistamab Combined with Autologous Lymphocyte Infusion in Relapsed/Refractory Multiple Myeloma
- Phase 3 Randomized Study of JNJ-79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After Prior PI, IMiD, and Anti-CD38 Therapy
Data & Insights
Has run more than one trial at 169 of 321 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in studying novel therapeutic approaches for multiple myeloma, with particular focus on both newly diagnosed and relapsed/refractory cases. Their research encompasses evaluation of innovative treatments including elranatamab, belantamab mafodotin, and anitocabtagene autoleucel.
- Post-transplant maintenance therapy
- Combination therapy approaches
- Novel immunotherapy agents
Myeloproliferative Disorders
The investigator conducts extensive research in myelofibrosis and related myeloproliferative conditions. Their work includes studies of navitoclax, pacritinib, and fedratinib, particularly focusing on patients with various forms of myelofibrosis including primary, post-polycythemia vera, and post-essential thrombocythemia.
- Spleen volume reduction therapies
- JAK inhibitor treatments
- Essential thrombocythemia management
Blood Disorders
The investigator focuses on various blood disorders including primary immune thrombocytopenia and polycythemia vera. Their research extends to novel treatments such as rusfertide and combination therapies for these conditions.
- Thrombocytopenia treatments
- Antithrombin deficiency management
- Hematocrit control strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.